Genmab A/S GMAB
Genmab A/S (Nasdaq: GMAB) is an oncology drug developer. Its lead program, Epcoritamab (EPKINLY/TEPKINLY), is in Phase 3 for relapsed/refractory DLBCL and follicular lymphoma; frontline DLBCL combination in Phase 3.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Epcoritamab (EPKINLY) with AbbVie | R/R DLBCL, R/R FL (approved); 1L DLBCL, FL combinations (Phase 3) | antibody | Approved |
| Tivdak (tisotumab vedotin) with Pfizer | recurrent/metastatic cervical cancer | antibody | Approved |
| Rinatabart sesutecan (Rina-S, GEN1184) | FRa-expressing ovarian and endometrial cancers | antibody | Phase 3 |
| Petosemtamab | 1L and 2L/3L recurrent/metastatic HNSCC | antibody | Phase 3 |
| GEN1059 (BNT314) | — | antibody | Phase 1 |
| GEN3018 | — | antibody | Phase 1 |
| GEN1079 | — | antibody | Phase 1 |
| GEN1106 | — | antibody | Phase 1 |
Recent results and decisions
- Oct 23, 2026met Phase 3 RAINFOL-02 trial met primary endpoint of PFS and key secondary endpoint of OS with rinatabart sesutecan versus chemotherapy in platinum-resistant ovarian cancer.
Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator's choice chemotherapy
Filing - Oct 5, 2026met Phase 3 EPCORE DLBCL-2 (epcoritamab + R-CHOP vs R-CHOP, newly diagnosed DLBCL, IPI 2-5) met PFS: 51% risk reduction, HR 0.49 (95% CI 0.36-0.67), p<0.0001.
The risk of disease progression or death was reduced by 51% (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001).
Filing - Jun 29, 2026met Phase 3 EPCORE DLBCL-4 (epcoritamab + lenalidomide vs R-GemOx, R/R DLBCL) met primary objective: PFS HR 0.40 (p<0.0001) U.S. censoring, HR 0.44 (p<0.0001) ex-U.S.
Based on topline results, the trial met its primary objective, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS).
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.